Organotypic Models for Functional Drug Testing of Human Cancers  

作　　者：Yu Ling Huang Lindsay K.Dickerson Heidi Kenerson Xiuyun Jiang Venu Pillarisetty Qiang Tian Leroy Hood Taranjit S.Gujral Raymond S.Yeung 

机构地区：[1]Division of Human Biology,Fred Hutchinson Cancer Center,Seattle,WA,USA [2]Department of Surgery,University of Washington,Seattle,WA,USA [3]National Research Center for Translational Medicine,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai,China [4]Institute for Systems Biology,Phenome Health Institute,Seattle,WA,USA

出　　处：《Biomedical Engineering Frontiers》2023年第1期103-112,共10页生物医学工程前沿（英文）

基　　金：This research was funded by the Department of Defense(DOD-AMRAA/W81XWH-19-1-0546 to V.P.,T.S.G.,and R.S.Y.);National Institutes of Health(R01 CA181445 to V.P.and T.S.G.);the Fibrolamellar Cancer Foundation(T.S.G.);the American Cancer Society(RSG-19-197-01-CDD to T.S.G.);the Climb to Fight Cancer Fellowship(Y.L.H.).L.K.D.is the recipient of a Cancer Research Institute/Fibrolamellar Cancer Foundation Postdoctoral Fellowship(CRI Award#4093).

摘　　要：In the era of personalized oncology,there have been accelerated efforts to develop clinically relevant platforms to test drug sensitivities of individual cancers.An ideal assay will serve as a diagnostic companion to inform the oncologist of the various treatments that are sensitive and insensitive,thus improving outcome while minimizing unnecessary toxicities and costs.To date,no such platform exists for clinical use,but promising approaches are on the horizon that take advantage of improved techniques in creating human cancer models that encompass the entire tumor microenvironment,alongside technologies for assessing and analyzing tumor response.This review summarizes a number of current strategies that make use of intact human cancer tissues as organotypic cultures in drug sensitivity testing.

关 键 词：CANCER HORIZON HUMAN 

分 类 号：R318[医药卫生—生物医学工程]